Blood test could predict melanoma treatment failure

NCT ID NCT04866680

Ongoing Knowledge-focused Sponsor: Institut de Cancérologie de Lorraine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether analyzing tumor DNA in the blood can help monitor melanoma after surgery. Researchers will collect blood samples from 136 patients before and after surgery, and every 3-4 months, to see if changes in DNA levels predict when a treatment stops working. The goal is to find a simple way to detect resistance early, so doctors can adjust treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that helps doctors spot melanoma treatment resistance early, allowing quicker changes in therapy.
What could go wrong: This is an observational study, not a treatment trial. It may not prove that ctDNA monitoring improves outcomes, and results might not apply to all melanoma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

CGFL

Dijon, France
CHU Jean Minjoz

Besançon, France
Chru Lille

Lille, France
Chru Nancy

Vandœuvre-lès-Nancy, France
Chu Dijon

Dijon, France
Ghr Mulhouse Sud Alsace

Mulhouse, France
Institut Godinot

Reims, 51100, France
Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, 54519, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.